Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors Page 1

CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members of the Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience, having overseen in various roles the approval of 15 novel treatments addressing unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders.

Michael Amoroso, Chairman of the Board of Abeona, said, “We are pleased to welcome Bernie Zeiher and Eric Crombez to our Board of Directors during this important time in Abeona’s history. As recognized and dynamic leaders in the life sciences, they bring a wealth of diverse drug development expertise to Abeona. We look forward to their valuable insights as we continue to focus on delivering pz-cel to patients with recessive dystrophic epidermolysis bullosa and as we seek to advance and expand our pipeline.”

Dr. Zeiher spent more than 10 years at Astellas Pharma, where he held various roles of increasing responsibility in drug development, culminating in his role as CMO, where he led early and late stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance. Prior to Astellas, Dr. Zeiher held various drug development leadership roles at other pharmaceutical companies, including Pfizer and Eli Lilly and Company. He also practiced medicine at a tertiary medical center in Indianapolis. Dr. Zeiher currently serves on multiple boards of publicly traded companies, including Entrada Therapeutics and Amylyx Pharmaceuticals, Inc. He previously served on the boards of TransCelerate Biopharma, Biotechnology Innovation Organization, and Astellas Global Health Foundation. Dr. Zeiher earned a BS in Biology from the University of Toledo and an MD from Case Western Reserve University School of Medicine. He completed his internal medicine residency and residency at the University Hospitals of Cleveland and then completed his medical residency as a Pulmonary and Critical Care Fellow at the University of Iowa Hospitals and Clinics.